Chung-ming Hsieh

Title: Innovations of Chung-ming Hsieh

Introduction

Chung-ming Hsieh is a notable inventor based in Newtown, MA (US). He has made significant contributions to the field of biotechnology, particularly in the development of proteins that interact with interleukin-1 (IL-1) cytokines. With a total of 2 patents, his work has implications for treating various IL-1-related disorders.

Latest Patents

Hsieh's latest patents include innovations related to IL-1 binding proteins. The first patent describes proteins that bind IL-1α and IL-1β, detailing their use in compositions and methods for treating, preventing, and diagnosing IL-1-related disorders. Additionally, it covers the detection of IL-1α and IL-1β in cells, tissues, samples, and compositions. The second patent focuses on IL-1β binding proteins, including chimeric, CDR-grafted, and humanized antibodies that exhibit high affinity for IL-1β and neutralize its activity. These binding proteins are useful for detecting IL-1β and inhibiting its detrimental effects in human subjects suffering from related diseases.

Career Highlights

Chung-ming Hsieh is currently associated with AbbVie Inc., a global biopharmaceutical company. His work at AbbVie has allowed him to contribute to cutting-edge research and development in the field of immunology and therapeutic proteins.

Collaborations

Hsieh has collaborated with notable colleagues, including Chengbin Wu and Dominic J Ambrosi. These collaborations have further enhanced the scope and impact of his research in the biotechnology sector.

Conclusion

Chung-ming Hsieh's innovative work in the development of IL-1 binding proteins showcases his significant contributions to biotechnology. His patents reflect a commitment to advancing medical science and improving treatment options for patients with IL-1-related disorders.